-
Innovation Ranking
NewInnovation Ranking – Sosei Heptares
Sosei Group Corp (Sosei) is a biopharmaceutical company that develops and commercializes drugs. Its medical products include Ultibro, Seebri, Enerzair, Breezhaler, and Oravi. The company's in-house pipeline programs include H4 antagonist, EP4 antagonist, SARS-CoV-2 MPro, GPR52 agonist and PAR2 mAb. Sosei partnered pipeline program comprises Adenosine A2a antagonist, GLP-1 agonist, CCR6 antagonist, MC4 antagonist, CGRP antagonist, GPR35 agonist, CXCR4 mAb, PAR2 Peptide, targeted GPCR degradation, AI-augmented drug discovery, Ion Channels, mGlu5 NAM and OX2 agonists. It develops medicines in the...
-
Product Insights
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Metabotropic glutamate receptor 5 (mGluR5) is a G protein-coupled receptor. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol calcium second messenger system and generates a calcium activated chloride current. The Metabotropic Glutamate Receptor 5 pipeline drugs market research report provides comprehensive information on the therapeutics under development for Metabotropic Glutamate Receptor 5, complete with analysis by stage of development, drug target, mechanism...
-
Track & Monitor
Pharmaceuticals Industry Deals and Trends in November 2021 – Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)
The pharmaceutical and healthcare market reported 503 deals worth $47.5 billion in November 2021. The market registered an increase in the number of mergers and acquisitions (M&As) including asset purchases. Capital raising, through equity and debt offerings, reported an increase in the number of deals and a decrease in deal values. The Pharmaceuticals Industry Deals and Trends report provides data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As), and financings in the pharmaceutical industry. The report portrays detailed...
-
Sector Analysis
Migraine Drug Market Size, Share & Trends Analysis and Forecast by Strategic Competitor Assessment, Market Characterization, Unmet Needs, Clinical Trial Mapping and Implications 2020 – 2030
The global sales for migraine drugs have been valued at $4.6 billion in 2020 with a CAGR of more than 9%. The US has dominated the migraine market, contributing to more than 80% of the sales in the seven major pharmaceutical markets (7MM) covered - the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan. A high market share in US is attributed to the large migraine prevalent population, the costliness of branded drugs, and the number of...
-
Track & Monitor
Pharmaceuticals Industry Deals and Trends in July 2019 – Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)
GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for July 2019 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in July 2019. The report portrays detailed comparative data on the number of deals and their value in the last...
-
Track & Monitor
Partnerships, Licensing, Investments and M&A Deals and Trends for April 2016 in Pharmaceuticals
GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for April 2016 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in April 2016. The report portrays detailed comparative data on the number of deals and their value in the last...
-
Track & Monitor
Pharmaceuticals Industry Deals and Trends in August 2019 – Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)
GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for August 2019 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in August 2019. The report portrays detailed comparative data on the number of deals and their value in the last...
-
Sector Analysis
United Kingdom Diabetes Care Devices Market Outlook to 2025 – Glucose Monitoring and Insulin Delivery
GlobalData’s “United Kingdom Diabetes Care Devices Market Outlook to 2025” is a comprehensive databook report, covering key market data on the United Kingdom Diabetes Care Devices market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Glucose Monitoring and Insulin Delivery. The United Kingdom Diabetes Care Devices Market report provides key information and data on: • Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments....
-
Product Insights
Asthma Disease – Global Clinical Trials Review, H2 2019
GlobalData's clinical trial report, “Asthma Global Clinical Trials Review, H2, 2019" provides an overview of Asthma clinical trials scenario. This report provides top line data relating to the clinical trials on Asthma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...